Balyasny Asset Management
PRAX icon

Balyasny Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

Balyasny Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,333
Closed -$123K – 3176
2022
Q2 		$123K Buy
+3,333
New +$356K ﹤0.01% 2259

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Balyasny Asset Management's PRAX Position: Q3 2025 in Review

Balyasny Asset Management sold out of Praxis Precision Medicines (PRAX) in Q3 2025, closing a stake of 369,254 shares — an estimated $15.5M sold.

Balyasny Asset Management first reported a position in PRAX in Q3 2022 and held it in 5 quarters. The position peaked at $15.5M in Q2 2025. 152 funds tracked by Wall St. Rank hold PRAX as of Q3 2025.

  • Balyasny Asset Management reported no remaining Praxis Precision Medicines position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 369,254 Praxis Precision Medicines shares in Q3 2025, an estimated $15.5M.
  • Balyasny Asset Management first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 5 quarters.
  • Balyasny Asset Management's Praxis Precision Medicines position peaked at $15.5M in Q2 2025.
  • 152 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.